Kineret in the Treatment of Rheumatoid Arthritis

Overview

Objective of the study is to gain knowledge about the administration of Kineret in patients with rheumatoid arthritis in the daily routine treatment and not in controlled trials. In the current survey, the investigation of the response rate of Kineret regarding the date of onset of action, the efficacy, as well as the tolerability and safety are of particular interest.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: January 2016

Interventions

  • Drug: Anakinra

Clinical Trial Outcome Measures

Primary Measures

  • Disease Activity Score 28 (DAS28)
    • Time Frame: 0-52 weeks
    • The DAS28 measures the progress and improvement of Rheumatoid Arthritis. DAS28 values range from 2.0 to 10.0 while higher values mean a higher disease activity. A DAS 28 below the value of 2.6 is interpreted as Remission. Both the number of joints with tenderness upon touching and swelling are counted. In addition, the erythrocyte sedimentation rate is measured. Also, the patient makes a subjective assessment of disease activity during the preceding 7 days on a scale between 0 and 100, where 0 is “no activity” and 100 is “highest activity possible”.
  • ACR response
    • Time Frame: 0-52 weeks
    • The ACR (American College of Rheumatology) Criteria measures the effectiveness of treatments for Rheumatoid Arthritis. The ACR is reported as % improvement, comparing disease activity at two discrete time points.
  • Health Assessment Questionnaire
    • Time Frame: 0-52 weeks
    • The patients will at each visit complete a questionnaire about their health status and the impairment in usual activities due to the rheumatoid disorder.

Participating in This Clinical Trial

Inclusion Criteria

  • Informed consent by the patient – Rheumatoid arthritis – Previous methotrexate therapy with inadequate response Exclusion Criteria:

  • Pregnancy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Swedish Orphan Biovitrum
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Stefan Zeitler, MD, Study Director, Swedish Orphan Biovitrum GmbH

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.